Obagi Medical (OMPI) Tops Q2 View; Guides Q3 Below the Street
More News related to OMPI
- Canaccord Adams Maintains a 'Buy' on Obagi Medical Products (OMPI); Raises PT
- OBAGI Medical (OMPI) Posts Q3 EPS of $0.14, In-Line with Street; Guides
- Obagi Medical Products Reports Third Quarter 2009 Earnings
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
- Obagi Medical Products to Report Third Quarter 2009 Financial Results and Host a Conference Call on November 5, 2009
More News related to Earnings
- Highlights From SWHC Q2 Conference Call: First Qtr Reflected Results From Two Segments Under S&W Umbrella; Guides Below for Q3
- NASB Financial (NASB) Posts Q4 EPS of $0.77, Tops Views
- Highlights From Take-Two Interactive Softwares' (TTWO) Forecast Teleconference
- Saks (SKS) Restates Q3 EPS to $0.04, Up from $0.01
- Big Lots (BIG) Delivers With Strong Q3 Results and Guidance
Obagi Medical Products, Inc. (NASDAQ: OMPI) reports Q2 EPS of $0.20, 1 cent better than the analyst estimate of $0.19. Revenues for the quarter were $27.8 million, versus the consensus of $27.20 million.
Sees Q3 revs in the range of $25.5-$27.5 million, versus the consensus of $28.37 million, and EPS of $0.13-$0.15, versus the Street estimate of $0.22.
Obagi Medical Products, Inc., a specialty pharmaceutical company, develops and markets skincare products in the United States and internationally.
Related Categories
EarningsGuidance
Stocks Mentioned
+0.28Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
